ArticleAnnals of surgical oncology2025
Risk Factors and Survival Analysis of Spontaneously Ruptured Hepatocellular Carcinoma: A Retrospective Cohort Study in Bilateral Centers.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Adjuvant Sintilimab Plus Bevacizumab After Curative Resection of Spontaneously Ruptured Hepatocellular Carcinoma: Protocol for a Prospective, Exploratory, Single-Arm Study (CLEAR-2).Journal of hepatocellular carcinoma · 2026Article
- Relationship between spontaneous rupture of hepatocellular carcinoma (SRHCC) and long-term survival after anatomic liver resection.Journal of gastrointestinal oncology · 2025Article
- Reply to Letter to the Editor: Risk Factors and Survival Analysis of Spontaneously Ruptured Hepatocellular Carcinoma: A Retrospective Cohort Study in Bilateral Centers.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aimed to analyze risk factors for spontaneously ruptured hepatocellular carcinoma (HCC) and investigate the impact of spontaneous tumor rupture (STR) on the long-term survival of HCC patients treated by transcatheter arterial chemoembolization (TACE).
methodsA retrospective cohort of patients with a diagnosis of HCC was divided into the ruptured group and the non-ruptured group. Uni- and multivariate logistic regression analyses were performed for risk factors. The survival outcomes for the patients treated with hepatectomy, TACE, or best supportive care (BSC) in ruptured group were compared. The prognosis of HCC patients treated with TACE were compared using propensity score-matching (PSM).
resultsThe study enrolled 1103 HCC patients for risk factors analysis. Logistic regression analysis showed that male sex, liver cirrhosis, tumor protrusion, tumor diameter greater than 5 cm, macrovascular invasion, alpha fetoprotein (AFP) of 400 ng/mL or higher, and ascites were independent risk factors for STR. A COX regression analysis indicated that tumor diameter greater than 5 cm, AFP of 400 ng/mL or higher, and STR were independent prognostic factors for overall survival (OS). Furthermore, tumor diameter greater than 5 cm and macrovascular invasion were independent prognostic factors for progress-free survival (PFS). In ruptured group, treatment with hepatectomy indicated the best prognosis, followed by treatment with TACE and BSC. Also, in TACE group, the non-ruptured HCC patients had significant longer OS than the ruptured HCC patients, whereas PFS showed no statistical difference before or after PSM.
conclusionsMale sex, liver cirrhosis, tumor protrusion, tumor diameter greater than 5 cm, macrovascular invasion, AFP of 400 ng/mL or higher, and ascites are independent risk factors for STR. In ruptured group, treatment with hepatectomy indicated the best prognosis, followed by treatment with TACE and BSC. For the HCC patients treated with TACE, STR was independent prognostic factor for OS but not PFS.
Indexed as
Identifiers
40205148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.